Item 2.01
Completion of Acquisition or Disposition of Assets
As described in the Introductory Note above, on July 31, 2018, Merger Sub irrevocably accepted for payment all Shares validly tendered and not validly withdrawn pursuant to the Offer on or prior to the Expiration Date. On July 31, 2018, the Merger was completed pursuant to Section 251(h) of the DGCL, with no vote of the Companys stockholders required to consummate the Merger. Upon the consummation of the Merger, Foundation Medicine became a wholly owned subsidiary of Roche Holdings.
The aggregate consideration paid by Merger Sub in the Offer and Merger to purchase all outstanding Shares (other than the Shares owned by Roche Holdings and its affiliates) and other equity-based interests of Foundation Medicine pursuant to the Offer and the Merger, was approximately $2.2 billion. Roche Holdings provided Merger Sub with the necessary funds to fund the Offer and the Merger from its cash on hand.
The information contained in the Introductory Note of this Current Report on Form 8-K is incorporated by reference into this Item 2.01.
